dMyelodysplastic syndromes (MDS) are a group of neoplasms characterized by ineffective myeloid hematopoiesis and various risks for leukemia. SRSF2, a member of the serine/arginine-rich (SR) family of splicing factors, is one of the mutation targets associated with poor survival in patients suffering from myelodysplastic syndromes. Here we report the biological function of SRSF2 in hematopoiesis by using conditional knockout mouse models. Ablation of SRSF2 in the hematopoietic lineage caused embryonic lethality, and Srsf2-deficient fetal liver cells showed significantly enhanced apoptosis and decreased levels of hematopoietic stem/progenitor cells. Induced ablation of SRSF2 in adult Mx1-Cre Srsf2 flox/flox mice upon poly(I):poly(C) injection demonstrated a significant decrease in lineage ؊ Sca ؉ c-Kit ؉ cells in bone marrow. To reveal the functional impact of myelodysplastic syndromes-associated mutations in SRSF2, we analyzed splicing responses on the MSD-L cell line and found that the missense mutation of proline 95 to histidine (P95H) and a P95-to-R102 in-frame 8-amino-acid deletion caused significant changes in alternative splicing. The affected genes were enriched in cancer development and apoptosis. These findings suggest that intact SRSF2 is essential for the functional integrity of the hematopoietic system and that its mutations likely contribute to development of myelodysplastic syndromes.
Multiple classes of genetic aberrations have been suggested as the cause of myelodysplastic syndromes (MDS) (1, 2), including mutations in signal transduction, transcription factors, and epigenetic modifiers (3-5). Interestingly, recent genomewide sequencing studies revealed that mutations in genes encoding splicing factors are commonly associated with MDS and other hematological malignancies (6-15). One of these newly identified genes codes for the SRSF2 splicing factor (also known as SC35), and its mutations have been linked to poor survival among MDS patients (16,17). Most of the SRSF2 mutations occurred at proline 95, and the majority of these mutations changed this proline to histidine (P95H); less-frequent changes to leucine (P95L) and arginine (P95R) and in-frame deletion of 8 amino acids (aa) from P95 to R102 (⌬8aa) have also been reported previously (6,16,(18)(19)(20). However, the causal effect of these mutations on MDS development remains to be established. SRSF2 is one of the founding members of the serine/argininerich (SR) protein family of splicing factors (21). It is involved in both constitutive and regulated splicing. Homozygous germ line Srsf2 knockout (KO) mice are embryonically lethal (22), and conditional knockout (cKO) mice display various tissue-specific phenotypes (22-24). Importantly, Srsf2 downregulation in mouse embryonic fibroblasts results in G 2 /M cell cycle arrest and genomic instability (23). To date, systematic analysis of SRSF2 function in the blood system has not been reported except for its requirement in T cell development (24). Given the tight link of Srsf2 mutations to MDS, we ai...